CRBP
Corbus Pharmaceuticals Holdings, Inc.NasdaqResearch view
$7.14−4.16%
Sep 25 close · 1D EOD · Databento
HealthcarePharmaceutical PreparationsSEC EDGAR FY 2022-12-31
The numbers · FY2022, filed
SEC EDGARRevenue$0
EPS, diluted$-5.90−60.30%
Debt / equity0.74
All filed figures
Snapshot
SEC EDGAR · FY 2022-12-31SectorHealthcare
Income—
Sales$0
Book/sh$1.71
Cash/sh$0.91
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio—
Current Ratio4.76
Debt/Eq0.74
EPS (ttm)$-5.90
EPS this Y-60.3%
EPS past 3/5Y—
Sales past 3/5Y—
EPS Y/Y TTM-60.3%
Sales Y/Y TTM—
Shs Outstand19.34M
ROA—
ROE—
ROIC-214.9%
Gross Margin—
Oper. Margin—
Profit Margin—
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue by fiscal year
$4.8M
FY18
$36.1M
FY19
$3.9M
FY20
$881,705
FY21
$0
FY22
Operating leverage — margins
GrossOperatingNet
Financials, annual · income and cash flowSEC EDGAR · open ▸
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $4.8M | $36.1M | $3.9M | $881,705 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-56.7M | $-77.1M | $-122.8M | $-56.0M | $-39.8M |
| Net Income | $-55.7M | $-71.5M | $-111.3M | $-45.6M | $-42.3M |
| Diluted EPS | $-0.98 | $-1.12 | $-1.42 | $-11.15 | $-10.15 |
| Operating Cash Flow | $-30.1M | $-45.7M | $-99.7M | $-48.2M | $-37.5M |
| Free Cash Flow | $-32.4M | $-48.5M | $-100.2M | $-48.2M | $-37.6M |
Follow the news. Track the move.
CRBP story timeline
Company updates and connected market context, with the dated price move attached.
1
Stories
0
Direct
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.